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Objective: We aimed to evaluate the frequency of chromosomal aberrations and mutations in the k-ras or
Her-2/neu genes in surgical specimens of endometrial carcinoma and their association with clinico-
pathological ﬁndings.
Materials and methods: Fifty-four patients who were treated for endometrial cancer between April 2010
and May 2011 at the Kocaeli University Obstetrics and Gynecology Department, Kocaeli, Turkey were
enrolled in a prospective study. Clinical and histopathological ﬁndings were recorded. Genetic analysis,
which included the detection of chromosomal deletions and duplications, as well as k-ras and Her-2/neu
mutations, was performed on endometrial samples from surgical specimens.
Results: In 70% of cases, tumor size was >2 cm or covered the entire uterine cavity, affecting mostly
corpus (76%) and invading less than half of the myometrium (80%). Forty-six cases (86%) had
endometrioid-type carcinoma, and early stage (Stage I, 65%) and higher grade (Grade IIeIII, 66%) tumors
were predominant. Lymph node and lymphovascular involvement was positive in 11% and 28% of the
patients, respectively. Chromosomal aberrations (deletion or duplication) and Her-2/neu and k-ras mu-
tations were encountered in 44%, 15%, and 13% of surgical specimens, respectively. The most common
chromosomal aberration was dup(1q) (n ¼ 16). Oncogenic mutations in Her-2/neu or k-ras had no as-
sociation with the severity of endometrial cancer, but the presence of chromosomal aberrations, as a
whole or dup(1q) alone, were associated with higher tumor size, deeper myometrial invasion, advanced
stage or grade, lymphovascular invasion, and lymph node involvement (p < 0.05 for all).
Conclusion: Chromosomal aberrations, particularly dup(1q), are related to advanced disease in endo-
metrial cancer. Genetic analysis of cancer tissues may provide important insights in determining disease
prognosis.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Endometrial cancer is one of themost commonmalignant tumors
of the genital tract in women, causing ~74,000 deaths globally per
year [1]. Although there is no effective screening test, 75%of cases cans and Gynecology, Sakarya
Education Hospital, Sakarya,
basar).
bstetrics & Gynecology. Published bbe diagnosed at an early stage due to the symptomatic nature of the
disease [1,2]. This is the main reason why current treatment has a
good response. However, therapeutic success is poorer in advanced
stages, emphasizing the need for better prognostic markers that aid
in the planning of treatment [3]. Furthermore, disease recurrence in
early stage endometrial cancer that cannot be explained by known
prognostic factors has led researchers to investigate new prognostic
markers [1,4]. As a result, the need for prognostic factors that can
estimate the prognosis of patients with endometrial cancer has
become an intense focus of attention in recent years.y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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determining the prognosis of endometrial cancer [5,6]. Other fac-
tors known to have a prognostic role in endometrial cancer, include
age, histological type, histological grade, myometrial invasion,
lymphovascular and lymph node involvement, tumor size, perito-
neal cytology, hormone receptor status, cervical and adnexal
spread, intraperitoneal disease, and the type of treatment [2,7,8].
As withmany cancers, genetic changes play a role in the etiology
of endometrial cancer, and in some cases, they have been suggested
to be useful in the early diagnosis of endometrial cancer. For
example, mutations in the k-ras or Her-2/neu oncogenes has been
reported in 19e46% or 9e30% of endometrial cancer cases,
respectively [9,10]. In addition, previous studies have shown that
chromosomal duplication and deletion frequently occurs at chro-
mosomes 1, 3, 8, 10, and 20 in endometrial cancers [11].
Thus, chromosomal abnormalities, such as k-ras and Her-2/neu
oncogenic mutations, play an important role in the genetics of
endometrial cancer, and may be useful to estimate the prognosis of
disease and plan therapeutic management strategies.
In this study, we determined the frequency of chromosomal
deletions or duplications and k-ras and Her-2/neu oncogenic mu-
tations in endometrial tissue samples from endometrial cancer
patients, as well as assessing the potential relationship between
genetic results and clinicopathologic ﬁndings.
Materials and methods
Study design and patients
This was a prospective, single-arm study from a single institu-
tion in Turkey. Fifty-four patients who were diagnosed with
endometrial cancers and treated at Kocaeli University Obstetrics
and Gynecology Department, Kocaeli, Turkey between April 1, 2010
and May 31, 2011 were included in the study. Other inclusion
criteria included complete staging studies, adequate tissue sample,
and regular postoperative follow-up. Patients who received neo-
adjuvant therapy were excluded from the study.
The surgical operation was a total abdominal hysterectomy
(TAH) with a bilateral salpingo-oophorectomy (BSO; TAH þ BSO) in
eight patients, TAH þ BSO þ bilateral pelvic lymph node dissection
(LND) þ omentectomy in 14 patients, TAH þ BSO þ pelvic and
paraaortic LND þ omentectomy in 14 patients,
TAH þ BSO þ bilateral pelvic LND in 16 patients, and
TAH þ BSO þ omentectomy in two patients.
The study protocol was approved by the Institutional Ethics
Committee of Kocaeli University and was conducted in accordance
with the latest version of the Helsinki Declaration. Each patient was
informed on the study and signed the consent form before
participation.
Clinical and histopathological ﬁndings
Clinical and histopathological ﬁndings included menopausal
status, age at diagnosis, concomitant diseases and therapies, clin-
ical outcome, endometrioid versus nonendometrioid type, tumor
size, extent of myometrial invasion, stage, and histopathologic
grade (according to the International Federation of Gynecology and
Obstetrics system) [12], and lymph node and lymphovascular
involvement.
Genetic analysis
Surgical uterine specimens from all patients were sent to the
Pathology Department of Kocaeli University for frozen-section ex-
amination. Endometrial sampling was performed on uterinespecimens with adequate tumoral tissue, and samples were stored
at80C until they were evaluated in the Laboratory of theMedical
Genetic Department, Kocaeli University. Sampling and storing was
performed under sterile conditions.
Detection of chromosomal deletions and duplications
An array-based comparative genomic hybridization (aCGH)
method was used to determine the chromosomal deletions and
duplication in tissue samples. Genomic DNA was isolated using the
DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). The quality
and quantity of DNA was determined using agarose gel electropho-
resis and a spectrophotometer (NanoDrop ND-1000; NanoDrop
Technologies, Wilmington, DE, USA), respectively. CytoChip Focus
Constitutional (BlueGnome, Cambridge, UK) was used as an aCGH
platform. DNA with adequate quantity and quality, as well as refer-
ence DNA (Human Genomic DNA, Female; Promega Corporation,
Madison, WI, USA), were marked, combined, and hybridized with
aCGH microchips at 47C for 20 hours in accordance with CytoChip
protocol. The microchips were then washed with different dilutions
of 20 saline-sodium citrate according to the protocol and scanned
with an Agilent Microarray Scanner (Agilent Technologies, Palo Alto,
CA, USA). Scanned images were evaluated quantitatively, and all of
the chromosomal copy number variationswere analyzed for deletion
and duplication with ﬁxed CytoChip algorithm settings in BlueFuse
Multi software (version 2.2, BlueGnome, Cambridge, UK; Figure 1).
Detection of k-ras mutations
Genomic DNAwas scanned for seven k-rasmutations located in
codons 12 and 13 on a LightCycler 480 real-time polymerase chain
reaction device (Roche Diagnostic GmbH, Mannheim, Germany)
with a TheraScreen k-rasMutation kit (Diagnostic Innovations Ltd.,
St. Asaph, UK). The difference between the threshold cycle of the
sample assay and the threshold cycle of the corresponding endog-
enous reference was calculated. The cut-off corresponding endog-
enous reference value for positive mutations was deﬁned as < 1%.
Detection of Her-2/neu mutations
In genomic DNA, 101-bp Her-2/neu fragments were ampliﬁed
with speciﬁc primers in accordance to the Way2Gene protocol and
analyzed using marked probes compared with standard samples in
LightCycler 480 real-time polymerase chain reaction device (Roche
Diagnostic GmbH). An ampliﬁcation ratio of <2 was considered to
be negative, whereas those >2 were considered positive.
Statistical analysis
The study datawere summarized with descriptive statistics, e.g.,
mean, standard deviation, number, and percentage. The frequency
of the oncogenic mutations and chromosomal aberrations were
analyzed with respect to the histopathological ﬁndings using the
Chi-square and ManneWhitney tests for two subgroups, as well as
analysis of variance for more than two subgroups. The statistical
analysis was performed using the SPSS 12 (SPSS Inc., Chicago, IL,
USA) software package. Odds ratios and 95% conﬁdence intervals
were calculated. The statistical signiﬁcance level was set to p < 0.05.
Results
Study population
The mean age of the 54 study patients at the time of diagnosis
was 62.5 ± 14.5 years (range, 33e85 years), andmost patients (80%)
Figure 1. Outcome of choromosomal copy number variation analysis by BlueFuse Multi software (BlueGnome, Cambridge, UK).
Table 1
Demographic, clinical, and histopathological characteristics of patients.
Parameter Outcome (n ¼ 54)
Age (y) 62.6 ± 11.5
Body mass index (kg/m2) 34 ± 9.07
Menopause status Premenopausal 11 (20)
Postmenopausal 43 (80)
Recurrent disease 6 (11)
Death due to disease 3 (5)
Histological type Endometrioid (Type 1) 46 (86)
Nonendometrioid (Type 2) 8 (14)
Stage I 35 (65)
II 9 (16)
III 7 (13)
IV 3 (6)
Grade I 18 (34)
II 22 (40)
III 14 (26)
Myometrial invasion <1/2 43 (80)
>1/2 11 (20)
Lesion site Corpus 41 (76)
Fundus 8 (15)
Fundus-corpus 5 (9)
Tumor size (cm) <2 16 (30)
>2 27 (50)
Entire cavity 11 (20)
Lymphovascular invasion Positive 15 (28)
Negative 39 (72)
Lymph node involvement Positive 6 (11)
Negative 48 (89)
Cytology of abdominal ﬂuid Positive 4 (8)
Negative 50 (93)
Data are presented as n (%) or mean ± standard deviation.
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m2; range, 23.4e48.2 kg/m2) indicated that the majority of patients
were obese. Of the patients, 40% had concomitant hypertension,
7.2% had diabetes mellitus, and 21.8% had hypertension and dia-
betes mellitus. Thirty-two patients (59%) received postoperative
radiotherapy. Upon follow-up, endometrial carcinoma recurrence
was observed in 11% of patients, and three patients (5%) died due to
the disease (Table 1).
Histopathology of surgical specimens
In 70% of cases, the tumor size measured >2 cm or covered the
entire uterine cavity, affecting mostly corpus (76%) and invading
less than half of the myometrium (80%). Histopathological ﬁndings
on surgical specimens showed that 46 patients (86%) had
endometrioid-type carcinoma. Early stage (Stage I, 65%) and higher
grade disease (Grade IIeIII, 66%) were predominant among the
cohort. Lymph nodes and lymphovascular involvement was posi-
tive in 11% and 28% of the patients, respectively (Table 1).
Genetic analysis
Chromosomal aberrations (deletion or duplication) or muta-
tions inHer-2/neu or k-raswere encountered in 44%,15%, and 13% of
surgical specimens, respectively (Table 2). The observed chromo-
somal aberrations were as follows: duplication of chromosome 1
[dup(1q), n ¼ 16], duplication of chromosome 10 [dup(10q), n ¼ 7],
mixed aneuploidy (n ¼ 4), duplication of chromosome 7 [dup(7q),
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(n¼ 2), monosomy 4, 9, 18, X (n¼ 1 for each), trisomy 4, 6, 11 (n¼ 1
for each), and deletion of chromosome 4 [del(4p), n ¼ 1]. No sig-
niﬁcant correlation was observed between the patient's age and
mutation in either k-ras or Her-2/neu (p ¼ 0.610 and p ¼ 0.555,
respectively). However, the frequency of chromosomal aberrations
was shown to increase signiﬁcantly with age (p ¼ 0.014).
No signiﬁcant relationship was observed between oncogenic
mutations in either k-ras or Her-2/neu and the following histo-
pathological ﬁndings: histological type, stage, grade, myometrial
invasion, tumor size, lymph node involvement, or lymphovascular
invasion (p > 0.05 for all; Table 3). No signiﬁcant difference in k-ras
or Her-2/neu oncogenic mutations or chromosomal aberrations was
detected between early and advanced disease stages (Stage I vs.
IIeIV) and grades (Grade I vs. IIeIII). Importantly, however, samples
with a higher rate of chromosomal aberrations and dup(1q) was
associated with larger tumor size, deeper myometrial invasion,
advanced disease stage or grade, lymphovascular invasion, and
lymph node involvement (p < 0.05 for all; Table 3). Clinicopaho-
logical parameters, chromosome aberrations, and abnormality of k-
ras and Her-2 genes are evaluated in Type I and Type II endometrial
cancers. The values are shown in Table 3.
Chromosomal aberrations were regarded as signiﬁcant risk
factors for stage, grade, myometrial invasion, tumor size, and lymph
node involvement (p < 0.05) by univariate analysis. Tumor size was
an independent risk factor on multivariate analyses (Table 4).Discussion
Endometrial cancer is a tumor characterized by the invasion of
endometrial tissue into the underlying stroma, myometrium, and
vascular tissues. Microscopically, endometrial cancer presents as a
marked hyperplasia and anaplasia of glandular elements [13]. Un-
derstanding the molecular biology and genetics of endometrial
cancer has recently become a major focus of research to develop
novel therapies, better estimate the relative risk and prognosis of
the disease, and more accurately predict treatment response
[3,5,14,15]. Although genetic polymorphisms that are associated
with endometrial cancer risk or prognosis have been identiﬁed in
various studies, the clinical signiﬁcance of these genetic poly-
morphisms is currently unclear [4,15].
To assess the underlying genetics and their effects on clinical
endometrial cancer, we characterized chromosomal aberrations,
including deletions, duplications, or oncogenic mutations in k-ras
or Her-2/neu, in endometrial tissue samples that were harvested
from patients diagnosed with endometrial cancer and assessed
whether a relationship exists between speciﬁc genetic events and
clinicopathologic ﬁndings. Our study population consisted mostly
of patients with endometrioid types of endometrial cancer at early
stages but with advanced histopathological grade. Although the
majority of patients had tumors larger than 2 cm, we observed that
lymph node and lymphovascular involvement, as well as myo-
metrial invasion were limited. Chromosomal aberrations (deletionTable 2
Mutations in k-ras and Her-2/neu oncogens and chromosomal aberrations.
n (%)
k-ras mutation Positive 7 (13)
Negative 46 (87)
Her-2/neu mutation Positive 8 (15)
Negative 46 (85)
Chromosomal aberrations Positive 24 (44)
Negative 30 (56)or duplication events) or mutations in Her-2/neu or k-ras were
detected in 44%, 15%, and 13% of surgical specimens, respectively.
Previous data suggests that the frequency of oncogene mutation
in endometrial cancer differs by race [16]. Therefore, local data may
represent an important factor when evaluating oncogenic muta-
tions in endometrial cancer. Here, we evaluated the frequency of k-
ras and Her-2/neu oncogene mutations in endometrial cancer
samples. It is known that mutations in the k-ras oncogene plays an
important role in the tumorigenesis of female genital tract cancers
[17,18]. However, conﬂicting data in literature has questioned the
prognostic value of mutant k-ras in endometrial cancer. Whilework
done by Alexander-Sefre et al [6] suggests that k-ras mutations
correlate with myometrial invasion depth, a study done by Esteller
et al [19] showed that although point mutations at codon 12 of the
k-ras oncogene occurred in eight of 55 (14.5%) tumor specimens, no
correlation was observed between k-ras oncogene mutation and
prognosis. However, studies from Japan, where endometrial cancer
has a lower incidence but a higher mortality rate than Europe and
the USA, reported higher rates of k-ras mutation, ranging from
12.2% to 40% [20e23]. In addition, these studies suggested that k-
ras mutations are related to advanced disease, aggressiveness, and
mortality [20e23].
Ito et al [24] found a signiﬁcant association between k-rasmuta-
tions and the presence of lymph node metastases and negative dis-
ease outcome in 221 cases of endometrioid endometrial cancer.
Similar to previous reports from the USA and Europe, we detected k-
rasmutations in13%of surgical specimens. In contrast to reports from
Japan, we did not ﬁnd any signiﬁcant effect of k-rasmutations on the
histological type of tumor, grade, surgical stage, depth ofmyometrial
invasion, lymphovascular invasion, lymph node involvement, and
tumor size. Furthermore, k-rasmutations were not detected in three
out of the 54 patients who died during follow-up.
Mutations in the Her-2/neu oncogene are also a potential
carcinogenic mechanism of endometrial cancer [25]. Over-
expression of Her-2/neu occurs in 10e21% of endometrial cancer
and correlates with intraperitoneal spread of disease and poor
survival [26e29]. Oncogenic aberrations in Her-2/neu have also
recently been suggested as an independent prognostic factor in
Type I endometrial adenocarcinoma [30,31], and Her-2/neu ampli-
ﬁcation correlates with histological grade of endometrium cancer
[32,33]. In our study, Her-2/neu mutations were detected in 15% of
the surgical specimens. However, in contrast to previous reports,
our ﬁndings did not indicate a prognostic value of Her-2/neu in
endometrium cancer, as no signiﬁcant relationship was observed
between Her-2/neu mutations and the histological type of tumor,
grade, surgical stage, depth of myometrial invasion, lymphovas-
cular invasion, lymph node involvement, or tumor size.
The role of genetics in endometrial carcinogenesis was ﬁrst
demonstrated by the cytogenetic analysis of the total cellular DNA
content (ploidy). Genomic alterations are commonly manifested by
chromosomal aberrations. A recent study by Nesina et al [34]
demonstrated that the number of damaged chromosomes present
in the peripheral blood T-lymphocytes was increased in patients
with endometrial cancer comparedwith healthy individuals. In line
with this, Falck et al [35] reported recurrent numerical and struc-
tural chromosomal changes and chromosomal translocations have
been frequently detected in rat endometrial carcinomas.
Interestingly, ~20% of endometrial cancers with advanced stage
and undifferentiated histology have been shown to harbor cyto-
genetic abnormalities [36,37]. In an analysis of 174 endometrial
cancer patients, Susini et al [38] reported that aneuploidy was the
strongest independent predictor of poor prognosis. We detected
chromosomal aberrations (deletion or duplication), including the
most common dup(1q), in 44% of our cases. In our study population,
histological grade, surgical stage, depth of myometrial invasion,
Table 3
Correlation of histopathological ﬁndings to oncogen mutations and chromosomal aberrations.
k-ras mutation (þ) Her-2/neu mutation (þ) Chromosomal aberration (þ) Dup(1q) (þ)
Histological type Endometrioid 7 (15) 8 (17) 20 (44) 14 (30)
Nonendometrioid 0 (0) 0 (0) 4 (50) 2 (25)
p 0.577 0.336 0.732 0.756
Endometrioid type Type I 7 (18.9) 7 (18.9) 15 (40.5) 6 (20)
Type II 0 (0) 1 (5.9) 9 (52.9) 6 (40)
p 0.055 0.210 0.694 0.153
Stage I 4 (17) 5 (14) 12 (34) 8 (23)
II 0 (0) 1 (11) 4 (44) 2 (22)
III 2 (43) 2 (43) 4 (60) 4 (60)
IV 0 (0) 0 (0) 3 (100) 2 (66)
p 0.065 0.585 0.044 0.035
Grade I 3 (16) 2 (11) 4 (22) 2 (11)
II 4 (18) 4 (18) 12 (54) 9 (40)
III 0 (0) 2 (14) 8 (57) 5 (36)
p 0.102 0.818 0.041 0.08
Myometrial invasion <1/2 5 (12) 6 (14) 15 (35) 10 (23)
>1/2 1 (9) 2 (18) 9 (82) 6 (54)
p 0.621 0.621 0.04 0.043
Tumor size <2 cm 2 (13) 3 (19) 1 (6) 1 (6)
>2 cm 4 (13) 5 (16) 18 (58) 12 (39)
Entire cavity 1 (14) 0 (0) 5 (71) 3 (43)
p 0.993 0.291 0.001 0.029
Lymphovascular invasion Positive 1 (7) 1 (7) 10 (66) 7 (46)
Negative 6 (15) 7 (18) 14 (35) 9 (23)
p 0.363 0.281 0.041 0.089
Lymphnode involvement Positive 1 (17) 0 (0) 5 (83) 4 (66)
Negative 6 (13) 8 (17) 19 (40) 12 (25)
p 0.775 0.279 0.042 0.037
Data are presented as n (%) or mean ± standard deviation.
Table 4
Logistic regression analysis. Outcomes of the 54 patients analyzed by univariate and multivariate analyses using clinicopathological parameters and the genomic markers.
Univariate model Multivariate model
OR % 95 CI p OR % 95 CI p
Lower Upper Lower Upper
Chromosomal aberration (þ)
Histological type 1.30 0.29 5.85 0.732
Endometrioid type 1.65 0.52 5.25 0.396
Stage 1.31 1.04 1.65 0.023
Grade 2.16 1.02 4.58 0.044
Myometrial invasion 8.40 1.60 43.98 0.012
Tumor size 6.76 1.95 23.35 0.003 6.76 1.95 23.35 0.003
Lymphovascular invasion 7.63 0.83 70.52 0.073
Lymph node involvement 3.57 1.02 12.56 0.047
CI ¼ conﬁdence interval; OR ¼ odds ratio.
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were signiﬁcantly associated with the presence of chromosomal
aberrations. Furthermore, chromosomal aberrations were detected
in all three patients who died during follow-up. Therefore, our
ﬁndings support the predictive value of chromosomal aberrations
as a bad prognostic marker in endometrium cancer.
Previous studies suggest that dup(1q) is an independent pre-
dictor of tumor aggressiveness and poor survival [39]. Therefore,
we analyzed the prognostic value of dup(1q) alone in endometrium
cancers. Similar to the data reported in the literature, we found that
dup(1q) was associated with higher tumor size, deeper myometrial
invasion, advanced stage or grade, lymphovascular invasion, and
lymph node involvement. Additionally, dup(1q) was present in two
of three patients who died during follow-up.
We acknowledge that the main limitation of our study was the
small sample size. This precludes us from reaching a deﬁnitive
conclusion on the prognostic value of oncogene mutations in
endometrial cancer. Therefore, the ﬁndings of the study will need
to be conﬁrmed with larger prospective studies.In conclusion, we showed that chromosomal aberrations,
particularly dup(1q), are related to advanced disease and poor
prognosis in endometrial cancer. Given that endometrial cancer is
the most common gynecologic cancer, and can be diagnosed
deﬁnitively by tissue biopsy via local intervention, the genetic
analysis of cancer tissue is important to determine disease prog-
nosis. As chromosomal analysis tests become more cost-effective
via technological advances, these tests will likely play a signiﬁ-
cant role in the management of endometrial cancer.Conﬂicts of interest
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